Results 181 to 190 of about 116,117 (334)

Eating Away at Antibiotic Resistance - Is Phage Therapy Our Future? [PDF]

Pathog Immun
Lederman MM, Bonomo RA.
europepmc   +1 more source

Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model

, 2019
Taruna Anand, Nitin Virmani, Sudarshan Kumar, Ashok Kumar Mohanty, Selvaraj Pavulraj, Bidhan Ch. Bera, Rajesh Kumar Vaid, Umang Ahlawat, Bhupendra Nath Tripathi   +8 more
openalex   +1 more source

Management of Diabetic Foot Infections Using Phage Therapy. [PDF]

Infect Drug Resist
Nazari M, Shokoohizadeh L.
europepmc   +1 more source

Face Transplantation [PDF]

, 2008

core   +1 more source

A Case for Anti‐IgE Vaccination

Allergy, EarlyView.
ABSTRACT Immunoglobulin E (IgE) plays a central role in allergic diseases by binding to the high‐affinity receptor FcεRI on mast cells and basophils, where allergen‐induced crosslinking triggers potent inflammatory responses. Various mechanisms by which IgE responses are generated and functionally regulated remain elusive despite many years of research.
Paul Engeroff, Zahra Gharailoo, Monique Vogel, Martin F. Bachmann   +3 more
wiley   +1 more source

Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration-A Review. [PDF]

Infect Dis Ther
Ayele AA, Liu W, Xiao M, Kalayu AA, Abegaz WE, Negash AA.   +5 more
europepmc   +1 more source

Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma

Allergy, EarlyView.
Staphylococcus aureus, commonly colonising CTCL patients, augments skin barrier dysfunction. Staphylococcal enterotoxins induce T‐cell release of barrier‐repressing cytokines (IL‐4, IL‐13, IL‐22, OSM). Cytokine signalling drives JAK‐dependent downregulation of filaggrin and loricrin in keratinocytes. Antibiotic‐mediated eradication of S. aureus induces
Maria Gluud, Emil M. Pallesen, Ziao Zeng, Martin R. J. Namini, Chella Krishna Vadivel, Lise Mette Rahbek Gjerdrum, Lang Yan, Sana Ahmad, Lise M. Lindahl, Michael Bzorek, Maria R. Kamstrup, Saptaswa Dey, Sisse Rye Ostrowski, Erik Sørensen, Pia Rantakari, Charlotte Menne Bonefeld, Carsten Geisler, Anders Woetmann, Riitta Lahesmaa, Lars Iversen, Peter Wolf, Thomas Litman, Terkild B. Buus, Niels Ødum   +23 more
wiley   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Synthetic cells for phage therapy: a perspective. [PDF]

Front Cell Infect Microbiol
Kulkarni V, Laohakunakorn N, Liyanagedera SBW.   +2 more
europepmc   +1 more source

A Comprehensive Review on Phage Therapy and Phage-Based Drug Development

Longzhu Cui, Shinya Watanabe, Kazuhiko Miyanaga, Kotaro Kiga, Teppei Sasahara, Yoshifumi Aiba, Xin-Ee Tan, Srivani Veeranarayanan, Kanate Thitiananpakorn, Huong Minh Nguyen, Dhammika Leshan Wannigama   +10 more
openalex   +2 more sources